| Presenter | Session Name | # | Abstract Title | Time | Location |
| Catherine Bjerum | Session 9 – Filariasis – Clinical, Immunology, Diagnostics | 35 | Moxidectin combination therapy for lymphatic filariasis is superior to ivermectin plus albendazole for clearance of microfilaremia at 12 months post-treatment | 8:00 – 8:15 am | Convention Center – Room 611/612 |
| Peter Fischer | Session 9 – Filariasis – Clinical, Immunology, Diagnostics | 36 | Partial macrofilaricidal activity of ivermectin, diethylcarbamazine and albendazole combination treatment for human onchocerciasis | 8:15 – 8:30 am | Convention Center – Room 611/612 |
| Bruce Rosa | Session 9 – Filariasis – Clinical, Immunology, Diagnostics | 39 | 19 Onchocerciasis Biomarker Candidates Identified Directly in Human Serum and Urine | 9:00 – 9:15 am | Convention Center – Room 611/612 |
| Sarah Greene | Session 14 – Poster Session A Presentations | 192 | A SARS-CoV-2 Antibody Lateral Flow Assay Provides a Semi-quantitative Assessment of Anti-Spike Antibody Responses After SARS-CoV-2 Vaccination | 11:00 – 12:45 pm | Convention Center – Hall 4A |
| Young-Jun Choi | Session 16 – Late-Breakers in Basic Science | LB-5161 | Distinguishing recrudescence from reinfection in lymphatic filariasis: a genomics-based approach for monitoring worm burden | 11:55 – 12:05 pm | Convention Center – Room 602/603/604 |
| Tania Supali | Session 35 – Filariasis – Epidemiology and Control | 608 | Detection of Brugia malayi eleven years after stopping mass drug administration to eliminate lymphatic filariasis in Belitung district, Indonesia | 4:15 – 4:30 pm | Convention Center – Room 611/612 |